Related Experiment Video
Updated: Oct 15, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Tropism and transduction of oncolytic adenovirus vectors in prostate cancer therapy
Chuang Wu1, Fu-Kun Wei1, Zi-Yang Xu1
1Department of Urology, The Affiliated Hospital of Xuzhou Medical University, 221002 Xuzhou, Jiangsu, China.
Abstract:
Oncolytic adenovirus has been applied in cancer therapy because of several advantages such as cost-effective production, high transduction efficiency and low toxicity. Recent efforts have been focused on the modification of oncolytic adenovirus by encoding transgenes within the viral genome to efficiently and selectively replicate within cancer cells, destroy cancerous cells, induce tumor cell apoptosis, and stimulate the recruitment of immune cells to the tumor site. Nevertheless, there are still big challenges for translational research of oncolytic virotherapy in clinical cancer management. Therefore, here we summarize current status on the design and application of oncolytic adenovirus vectors for prostate cancer therapy. In particular, we describe the main receptors associated with the tropism and transduction of oncolytic adenovirus vectors, and propose new directions in future studies for prostate cancer virotherapy.
Insights
Oncolytic adenovirus vectors show promise for prostate cancer therapy by selectively targeting and destroying cancer cells. Further research into vector design and tropism is crucial for successful clinical translation.
Area of Science:
- Oncolytic virotherapy
- Adenovirus vector engineering
- Prostate cancer therapeutics
Background:
- Oncolytic adenoviruses offer advantages like cost-effective production, high transduction efficiency, and low toxicity for cancer treatment.
- Modifications enhance oncolytic adenovirus capabilities, including selective replication in cancer cells, tumor destruction, apoptosis induction, and immune cell recruitment.
Purpose of the Study:
- To summarize the current status of oncolytic adenovirus vector design and application for prostate cancer therapy.
- To discuss key receptors influencing oncolytic adenovirus tropism and transduction.
- To propose future research directions for advancing prostate cancer virotherapy.
Main Methods:
- Review and summarization of existing research on oncolytic adenovirus vectors in prostate cancer.
- Analysis of viral tropism and transduction mechanisms mediated by specific receptors.
- Identification of challenges and opportunities for translational research.
Main Results:
- Oncolytic adenoviruses are a viable platform for prostate cancer therapy due to inherent advantages.
- Vector modifications can improve cancer cell targeting, destruction, and immune response.
- Understanding receptor interactions is key to optimizing viral tropism and transduction efficiency.
Conclusions:
- Oncolytic adenovirus vectors hold significant potential for prostate cancer treatment.
- Addressing translational challenges requires continued research into vector design and targeting strategies.
- Future studies should focus on enhancing vector specificity and efficacy for clinical application.
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...